key: cord-0867723-46am78kj
authors: Ilonzo, Nicole; Rao, Ajit; Berger, Kelsey; Phair, John; Vouyouka, Ageliki; Ravin, Reid; Han, Dan; Finlay, David; Tadros, Rami; Marin, Michael; Faries, Peter
title: Acute Thrombotic Events as Initial Presentation of Patients with COVID-19 infection
date: 2020-06-17
journal: J Vasc Surg Cases Innov Tech
DOI: 10.1016/j.jvscit.2020.05.011
sha: 0be4f70079ef4535358b0c6d02444bc4bad4e9ae
doc_id: 867723
cord_uid: 46am78kj

We describe three patients with COVID-19 who presented with an acute vascular event rather than typical respiratory symptoms. These patients were all subsequently found to have laboratory confirmed COVID-19 infections as the likely etiology of their thrombotic event. The primary presentation of COVID-19 infection as a thrombotic event rather than respiratory symptoms has not been described elsewhere. Our cases and discussion highlight the thrombotic complications caused by COVID-19, management of these patients, and explores the role of anticoagulation in patients diagnosed with COVID-19.

COVID-19 has a wide range of recognized presentations from asymptomatic carriers to 6 upper respiratory symptoms. Critically ill patients with COVID-19 also appear to have 7 significant thrombotic events and there is increasing evidence that the virus results in a 8 hypercoagulable state. 2 We describe three of several patients with COVID-19 who presented to 9

our health system primarily with symptoms from an acute vascular event rather than with 10 significant respiratory symptoms. As required by hospital policy, all patients had preoperative were for acute thrombotic events. Of these patients, we selected cases whose initial presentation 23 4 from COVID-19 infection was an ischemic event rather than significant respiratory symptoms 1 (Table I) . We excluded any patients with a history of a hypercoagulable disorder or significant 2 peripheral vascular disease. All patients had a hypercoagulability work-up including 3 antiphospholipid antibodies which were negative. For all cases, EKG was performed and was 4 sinus rhythm. Venous duplex was negative and transthoracic echocardiogram was unremarkable 5 without evidence of a PFO. All patients consented for this study. Patients with COVID-19 infection typically present to the hospital with respiratory 20 complains of cough, shortness of breath, and fever. . However, we describe three of several cases 21 at our institution in which the primary presentation was an acute thrombotic event rather than 22 typical upper respiratory symptoms. All patients presented with no or mild respiratory 23 6 complaints and were found to have laboratory confirmed COVID-19 infections during 1 preoperative testing. Notably, the patients in our cohort were relatively young with no significant 2 risk factors for thrombosis. None of these patients had a history of peripheral vascular disease. In 3 all cases, electrocardiogram (ECG) showed sinus rhythm and both lower extremity venous 4 duplex and Transthoracic Echocardiogram (TTE) were unremarkable. Furthermore, all patients 5 had a hypercoagulability work-up including antiphospholipid antibodies which were negative. 6

There is increasing evidence that patients with COVID-19 are prone to thrombotic 7 complications. Thrombotic events in patients with COVID-19 disease can in part result from 8 Disseminated Intravascular Coagulation (DIC). DIC is common in critically-ill patients with 9 sepsis which is thought to contribute to these thrombotic complications seen in COVID-19 10 patients. 3 In a study of 184 critically ill COVID-19 patients, arterial thrombosis was 3.7% and 11 venous thrombosis was 28%. 4 However, in all 3 of our cases, the COVID-19 infection was 12 asymptomatic or mild at the time of presentation. Interestingly, out of all 21 patients with 13 COVID-19 and thrombotic events at our institution, the majority had only mild or moderate 14 symptoms (85.72%) and were not critically ill. Thus, we suspect there may be another 15 underlying mechanism for hypercoagulability in these patients. Hypercoaguability may not 16 correlate with severity of COVID-19 infection. 17

Current studies have not delineated the mechanisms of large-vessel arterial thrombosis in 18 patients with COVID-19. Recent reports show localized thrombosis in the small pulmonary 19 vessels as well as diffuse microthrombi in small vessels throughout the body 5 . There is 20 increasing evidence that thrombosis may be due to endotheliitis 6 . The authors support the use of 21 therapeutic anticoagulation in admitted patients with COVID-19 infections. Additionally, 22 perhaps an anticoagulation regimen for patients who are at high-risk for thrombotic 23 complications and COVID-19 should be considered in the outpatient setting. More data is 1 urgently needed to develop evidence-based guidelines on anticoagulation management of 2 patients with COVID-19 infection. 3 4

What we know so far: COVID-19 current clinical knowledge and research

Standardization Committee on DIC, and the Scientific and Standardization Committee on 7

Perioperative and Critical Care of the International Society on Thrombosis and 8

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Severe 13 acute respiratory syndrome and venous thromboembolism in multiple organs

Endothelial cell infection and endotheliitis in COVID-19